2020
DOI: 10.1186/s13046-020-01763-z
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma

Abstract: Background Recent genomic analyses revealed that druggable molecule targets were only detectable in approximately 6% of patients with nasopharyngeal carcinoma (NPC). However, a dependency on dysregulated CDK4/6–cyclinD1 pathway signaling is an essential event in the pathogenesis of NPC. In this study, we aimed to evaluate the therapeutic efficacy of a specific CDK4/6 inhibitor, palbociclib, and its compatibility with other chemotherapeutic drugs for the treatment of NPC by using newly established xenograft mod… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 16 publications
(10 citation statements)
references
References 64 publications
0
10
0
Order By: Relevance
“…Chemotherapy is one of the most classical treatment modalities for malignant tumors, and depending on the type of tumor, chemotherapy can play a “leading” or “supporting” role in the treatment process [ 96 , 97 , 98 , 99 , 100 ]. For primary NPC, radiotherapy with chemotherapy is almost the accepted treatment modality, but the “role” of chemotherapy in the treatment of recurrent NPC is still debatable [ 101 , 102 , 103 ]. Currently, several publications have reported on the treatment of recurrent NPC using different chemotherapy regimens; many oncologists believe that for patients with rT1–rT2, retreatment with radiotherapy or surgery is an option.…”
Section: Treatment Of Recurrent Npcmentioning
confidence: 99%
“…Chemotherapy is one of the most classical treatment modalities for malignant tumors, and depending on the type of tumor, chemotherapy can play a “leading” or “supporting” role in the treatment process [ 96 , 97 , 98 , 99 , 100 ]. For primary NPC, radiotherapy with chemotherapy is almost the accepted treatment modality, but the “role” of chemotherapy in the treatment of recurrent NPC is still debatable [ 101 , 102 , 103 ]. Currently, several publications have reported on the treatment of recurrent NPC using different chemotherapy regimens; many oncologists believe that for patients with rT1–rT2, retreatment with radiotherapy or surgery is an option.…”
Section: Treatment Of Recurrent Npcmentioning
confidence: 99%
“…Whether these differently expressed proteins would affect the drug effect was further tested here. We chose a specific CDK4/6 inhibitor palbocilib [ 23 ] to verify if the expression of target proteins would affect the efficiency of the corresponding target drug which are kinases that control cells to enter into the cell cycle [ 24 ]. In this study, Hep3B cells with the confluence of 30%, 50%, and 70% were treated with palbociclib of the same concentration.…”
Section: Resultsmentioning
confidence: 99%
“…In this current study, we explored the antitumor effect of the targeted therapy palbociclib in three PDX chordoma models in order to consider the homozygous deletion of CDKN2A/2B as a theranostic biomarker of response to palbociclib, as suggested in other cancer types (43,54,55). We observed various responses to palbociclib concerning both models (CD3, CD7) harboring a loss of CDKN2A/2B, and no tumor efficacy in the non-CDKN2A/ 2B-deleted PBRM1-mutated PDX (CD39).…”
Section: Discussionmentioning
confidence: 99%